This may explain the relative low number [22,25,26] and frequency [25] of CTCs detected with EpCAM-based assays, particularly when compared to other metastatic diseases [13] and to EpCAM-independent assays [22,27,28]. Here, EPCAM is linked to metastatic neoplasm.